PHARMA LITERATI

Coming down heavily on Pharmacy Council of India (PCI) for its recommendation to universities to prefix 'Dr' before the names of those who pass out the Doctoral Pharmacy (Pharm D) course, the Indian Medical Association (IMA) has asked the national pharmacy education regulator to withdraw the contentious circular issued to the universities in this regard by the PCI Registrar last week. In a statement issued on May 29 against the circular of the PCI, the IMA says that the PCI’s circular is unlawful, and in violation of the rules and regulations governing the practice of modern medicine in the country. On several occasions, the Supreme Court of India held that only a person holding a registration with the ‘Medical Council of India’ or the state medical councils is entitled to practice modern system of medicines. As per the judgments and rulings of the apex court, the pharmacists cannot use ‘Dr’ prefix with their names. They are supposed to work under a medical supervision ...

Venue:    ,   Goa  ,   Goa   ,  India Starting Date:  30th May 2019 Ending Date:  31st May 2019 About the Event/Conference  : ISER- 595th International Conference on Science, Health and Medicine (ICSHM) is a prestigious event organized with a motivation to provide an excellent international platform for the academicians, researchers, engineers, industrial participants and budding students around the world to SHARE their research findings with the global experts. ICSHM 2019 will be held in Goa, India on 30th - 31st May, 2019.   Organized by:    ISER Contact Person:  Conference Coordinator Event enquiries email address:   info@iser.co Website :   http://iser.co/Conference2019/India/3/ICSHM/

The China-India joint summit held recently discussed bilateral trade to improve Indo- China pharma industry and address issues like long product registration time and high fees for product registration in China’s drug regulatory system, among other issues.  Besides this, other relevant key issues related to transparency in public procurement system in China and clinical trial related approvals were also deliberated at the summit organised under the aegis of Indian Pharmaceutical Association (IPA), Shengjie and SaSPinjara, China between May 16 and May 17, 2019 at Pullman Shanghai South, China. The summit was focused on enhancing export business for both the nations across the globe. Senior health ministry official from Government of Gujarat Punamchand Parmar was invited as the Chief Guest of the summit and Gujarat Food and Drugs Control Administration (FDCA) Commissioner Dr Hemant Koshia was invited as Guest of Honour.  Among other dignitaries, Dr. Anil Kumar Rai, Consulate Ge...

Watch our latest video on career guidance for pharmacy students about how can the students utilize the vacation time for building their profile. https://www.youtube.com/watch?v=LaxAiXBtouw Don't forget to like, share and subscribe to our youtube channel. 

Following its proposal to the state government to mandate issuance of sale licence for ayurvedic drugs, the Maharashtra Food and Drug Administration (FDA) has urged the state government for inclusion of the provision of “Licence for the sale of Ayurvedic drugs”, in the Drugs and Cosmetics (D&C) (Maharashtra Amendment) Act to effectively control spurious drugs sale.     Currently, the state FDA has no control on ayurvedic drugs beyond registering manufacturers. Under the existing norms, FDA has the power to seize spurious cosmetic or Ayurveda products but has no authority for prosecuting retailers found selling them. The state regulator in its ongoing crackdown for non-compliance to Drugs and Magic Remedies (Objectionable Advertisement) Act (DMR Act) 1954 revealed that ayurvedic drugs were mixed with allopathic medicines in contravention to the provisions of the DMR Act, 1954. Maharashtra also submitted reports of action taken for non-compliance to the state g...

Following Central Drugs Standard Control Organisation (CDSCO) having red-flagged three brands of pacemakers from US medical-device maker Medtronic and United States Food and Drug Administration (FDA) also issuing safety alert on the heart implants, Medtronic has advised physicians to continue normal patient follow-up with the pacemakers in accordance with standard practice and, where possible, to continue with remote monitoring.  While the devices continue to perform well within reliability projections, Medtronic has implemented additional process and component enhancements that have been reviewed and approved by FDA, Medtronic in a release stated.. A safety alert was also issued by the US FDA on these heart implants over concerns that their batteries drain out with no warning to the patient. The release further states, Medtronic has published a performance note about a rare mode in a population of Azure and Astra pacemakers and Percepta, Serena and Solara cardiac ...